RWE and Patient-Centered Outcomes
Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. When that evidence reflects patient outcomes, it provides an invaluable perspective on the consumer experience. Explore our real-world evidence (RWE) analyses and guidance to support your strategic decisions.
Rethinking Evidence Strategy in HEOR Budget Planning
Avalere experts in health economics and outcomes research (HEOR) identify four elements of evidence strategy development in Pharma Focus America.
Updated Negotiation ICR Presents New Industry Evidence Needs
Updates in the Initial IPAY 2027 ICR highlight the increasing needs for specific evidence planning and generation for industry to prepare for negotiation.
Rethink Evidence Strategy this HEOR Budget Planning Season
Budgeting season offers HEOR teams the opportunity to revisit research and evidence needs and update their commercialization strategy based on market dynamics.
Mental Health Treatment Integration Can Offer Cost Savings
Adequately treating mental health disorders can cut overall costs, including those from comorbidities, despite access barriers and high comorbidity expenses.
Establishing Value in an Uncertain and Dynamic Landscape
On June 5, The Evidence Base published an article entitled, “Navigating uncertainty: redefining healthcare value in an evolving healthcare landscape,” covering key topics from Avalere’s ISPOR theater session.
Five Data Strategy Questions Pharma Should Ask For 2025
When utilizing and acquiring data, life sciences companies should consider these top questions and key implications for their 2024–2025 strategic plans.
CMMI Quality Pathway Prioritizes Patient-Centered Value
Innovation models will prioritize improving quality and redefine how quality is measured.
Video: Discussing Value at Asembia and ISPOR
Ahead of the upcoming Asembia and ISPOR conferences, Avalere experts discuss the role of external assessors in value assessment.
Webinar: Valuing the Patient Perspective: Patient-Centered HTA
This expert panel will address the challenge of integrating patient perspectives into value assessments, discussing implications for evidence strategy, health equity, caregiver involvement, and downstream impacts on care delivery.
eBook: Rare Disease Biotechnology Landscape
In an eBook, Avalere and Avalere Health experts describe the policy, market access, and evidence landscape of rare disease in the United States and globally.
Drug Repurposing: Potential to Expand Rare Disease Treatment
Drug repurposing offers developers an opportunity to bring treatment options to patients at a reduced cost and shortened timelines, although challenges exist.
Limb Loss and Limb Difference: US Prevalence and Impact
Avalere and the Amputee Coalition analyzed claims data to understand the prevalence of limb loss and limb difference and the implications for public policy.
Video: Innovations in Patient-Centricity: How Rare Disease is Leading the Way
In this installment of our 2024 Trends Influencing Rare Disease series, Avalere experts dive into patient centricity trends in rare disease.
After a Rare Disease Diagnosis, Patient Utilization Rises
Healthcare resource utilization increased for Medicare FFS patients following diagnosis of an ill-defined rare disease.
Variation in Autoimmune Payer Mix Drives Channel Strategy
Variation in mix of payer coverage across autoimmune diseases highlights the need for manufacturers to assess patient payer mix to support channels of access.
Video: Quantifying Indirect Burden and Measuring Novel Elements of Value
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #10: Quantifying Indirect Burden and Measuring Novel Elements of Value
Top HEOR Trends: Quantifying Indirect Burden and Measuring Novel Elements of Value
Avalere experts dive into Trend #10: Quantifying Indirect Burden and Measuring Novel Elements of Value and discuss its evolving nature.
Assessing the Total Economic Burden of Rare Disease
Innovative research methods can be used to measure the total burden of rare disease, including direct medical costs, indirect costs, and overall life impacts.
2023 Top Trends in HEOR: Policy’s Pressure on HEOR
Avalere experts dive into Trend #9: Policy’s Pressure on HEOR and explore implications of recent policy developments on evidence strategies.
Video: Policy’s Pressure on HEOR
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #9: Policy’s Pressure on HEOR.